Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same

Abstract

Compositions and methods for the detection and treatment of ADHD are provided.

1 .- 46 . (canceled) 
     
     
         47 . A method of treating attention deficit hyperactivity disorder (ADHD) in a subject comprising administering an effective amount of a member of the piracetam family of nootropic agents, or a pharmaceutically acceptable acid addition salt or solvate thereof, to a subject with ADHD. 
     
     
         48 . The method of  claim 47 , wherein the subject has a copy number variation (CNV) in RANBP1. 
     
     
         49 . The method of  claim 48 , wherein the CNV is a duplication. 
     
     
         50 . The method of  claim 48 , wherein the CNV is a deletion. 
     
     
         51 . The method of  claim 48 , wherein the CNV is determined by detecting the presence of one or more single nucleotide polymorphisms (SNPs) between kgp15081773 and kgp240898. 
     
     
         52 . The method of  claim 48 , wherein the CNV is determined by detecting the presence of a single nucleotide polymorphism (SNP) on chromosome 22 between 18485023-18494706. 
     
     
         53 . The method of  claim 48 , wherein the CNV is determined by detecting the presence of single nucleotide polymorphism (SNP) rs2238798. 
     
     
         54 . The method of  claim 47 , wherein the member of the piracetam family of nootropic agents is (+)-5-oxo-D-prolinepiperidinamide, or a pharmaceutically acceptable acid addition salt or solvate thereof. 
     
     
         55 . The method of  claim 47 , wherein the member of the piracetam family of nootropic agents is (+)-5-oxo-D-prolinepiperidinamide monohydrate.